Indeed trabectedin (ET-743, Yondelis), a marine natural product approved as a second-line treatment of recurrent ovarian cancer (Monk et al., 2012), exhibits antiangiogenic activities by upregulating tumor cell expression of TSP-1 (Dossi et al., 2015). The gene discussed is THBS1; the disease is ovarian carcinoma.